Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

As the CEO of ProofPilot, Chris Venezia has a track record of success with more than 18 years of strong leadership in product commercialisation, patient recruitment, marketing, and sales. He joined ...

Elevidys has been given full approval to treat ambulatory patients with DMD, with an accelerated approval in non-ambulatory ...

The European Commission has approved PTC Therapeutics' treatment for the rare disease phenylketonuria (PKU), Sephience, ...

BIO 2025 this year came at a uniquely fraught moment for vaccination in the United States just days after HHS Secretary ...

Liquid biopsies are reshaping colon cancer detection, particularly in addressing the rise in early-onset cases.

That is the conclusion of a study in The Lancet, which has tracked the take-up of childhood vaccinations for diseases like ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...

The FDA has launched a review of clinical trials that plan to send American citizens' living cells to 'hostile' countries – ...

The STAAR trial showed that a one-shot dose of ST-920 – now known as isaralgagene civaparvovec – was able to improve kidney ...

Cambridge, Massachusetts-based Nuvalent has reported the results of its phase 1/2 ARROS-1 trial of zidesamtinib in previously ...

Trying to tackle all challenges at once will likely cause even more issues in the future; instead of spreading out, focus on ...